Increasing prevalence of cancer, favorable government initiatives, rising pressure to improve the quality of care and reduce healthcare costs, rising adoption of EHRs
Cancer Registry Software Market Overview
The cancer registry software market acquired a value of USD 56.4 million in 2018, and it will reach a CAGR of 10.7 % in the forecast period by 2027.
A cancer registry is a software database for organizing, collecting, and storing data of cancer patients for evaluation of their treatment outcomes. This software tool helps manage and provide access to information and build cancer registries.
The market’s growth is driven by the demand for proper management of cancer and the rising demand to improve the quality of care and reduce healthcare costs. The higher adoption of EHRs and the increased usage of cancer patient registry data for marketing surveillance are driving the market.
The usage of integrated software in the healthcare industry is mainly due to the changing landscape; the demand for proper streamlined and optimized workflows and decreased physician workloads are enhancing the market’s growth. Other factors such as the emerging government’s focus on population growth, health management, investment in the healthcare sector, and eliminating the higher healthcare costs will boost the market’s growth in the forecast period.Segmentation
The cancer registry software market has been segmented into type, deployment model, database type, functionality, and end user.
By type, the market has been segmented into integrated software and standalone software.
Based on the deployment model, the market has been segmented into cloud-based models and on-premise models.
On the basis of the database type, the market has been segmented into commercial databases and public databases.
By functionality, the market has been segmented into patient care management, product outcome evaluation, cancer reporting to meet state and federal regulations, medical research & clinical studies.
The market, by end user, has been segmented into hospitals & medical practices, government organizations & research centers, pharmaceutical, biotechnology, and medical device companies, and others.
The cancer registry software market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.
The European cancer registry software market has been segmented into Western Europe and Eastern Europe. Western Europe market has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.
The cancer registry software market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The market in the Middle East & Africa has been segmented into the Middle East and Africa.
Cancer registry software market, by Key Players
Regional Market Summary Cancer registry software market Share (%), by Region, 2018Source: White Papers, Company Presentations, Annual Reports
On a regional basis, the Americas is anticipated to dominate the cancer registry software market owing to the rising prevalence of cancer, innovative product development and increasing investment in research and development for innovation in the region. According to the National Cancer Institute, there were 1,735,350 new cases of cancer in the US in 2018.
Europe is expected to hold the second largest position in the market owing to the presence of strong academic & research base and availability of funding for research in the European countries.
Asia-Pacific is anticipated to be the fastest growing region in the market owing to the shift of pharmaceutical companies to countries such as India and China, which are low-cost manufacturing regions.
The Middle East & Africa has the least share of the cancer registry software market. Moreover, the major market share of the region is expected to be held by the Middle East region owing to the growing government initiatives for the healthcare sector.
by Deployment Model
by Database Type
by End User
In May 2022
Veeva Systems has declared that Lucid Diagnostics Inc., a commercial-stage, which is a cancer prevention medical diagnostics company with an owned subsidiary of PAVmed Inc., has selected Veeva Vault CDMS for capturing electronic data, coding, and data cleaning in the upcoming research EsoGuard in patients who are undergoing standard for, and management of, esophageal adenocarcinoma.
In May 2022
Taipei Veteran’s General Hospital is a first-class medical center and teaching hospital in Taiwan. TVGH and a major electronics brand joined forces in AI-based medicine for intensive care of early warning systems for shock and an individualized cancer treatment system.
Together, the hospital-private sector collaboration declared their result in the field of AI-based precision medicine. They established a warning system for shock in intensive care patients. In addition, the collaboration has led to the analysis of patients with hepatobiliary cancer, rectal, and gastrointestinal. It is used to predict a patient’s disease duration and treatment outcomes. Intended Audience
Cancer Registry Software Market was valued at USD 56.4 million in 2018.
The market is expected to exhibit a strong 10.7% CAGR over the forecast period from 2019 to 2024.
The increasing prevalence of cancer and the increasing adoption of electronic healthcare record systems are the major drivers for the global cancer registry software market.
Concerns related to data privacy are the major restraint on the cancer registry software market.
The Americas and Europe dominate the global cancer registry software market due to the widespread adoption of EHR systems.